Meet us at

01 June
Ankyras has been used in 260 Flow Diverter treatment cases. It was validated in 121 cases, where the simulated length of the device was compared to the real length of the implanted device, showing an accuracy of 92.6% in average (94.1% median).  
10 March
ANKYRAS receives CE certification. ANKYRAS Software receives CE marking approval, Annex II according to directive 93/42/EEC Medical Device.  
05 July
POROVIEW project. GALGO MEDICAL and the CONSORCI INSTITUT D INVESTIGACIONS BIOMEDICAS AGUST PI I SUNYER have obtained the approval of the project "Predictive Geometrical Model for personalized flow Diverter sizing and interventional Planning" (POROVIEW) from the Spanish Ministry of Economy and the European Union.  
14 Jan
Jacobo Gil de Biedma joins Galgo as Director of Business Development. Galgo Medical recently named Mr Jacobo Gil de Biedma as its new Director of Business Development.  
20 Oct
Inveready enters the capital of Galgo Medical. The venture capital firm Inveready participates in a round of 1million Euros for the medical software company Galgo Medical to move forward with its development and marketing efforts of its three product lines.  
15 Jun
French CIR qualification granted. Galgo Medical obtained the CIR qualification granted by the French Administration in recognition as an intensive research and development (R&D) SME. The qualification is granted for a period of two years.  

Galgo Medical
Predictive Software for Safer Treatment

Galgo develops 3D medical image post-processing software solutions to add predictive value to personalized treatment strategies. Each patient is different and requires tailored treatment: personalized medication, surgical implants and interventional strategies. The increasing availability of high-quality patient images enables Galgo's algorithms and software to extract key clinical information to support clinical decision-making and planning and guidance of interventional procedures.

Galgo has focused on four medical disciplines:

Intra-cranial aneurysms, to plan, for each patient, the endovascular treatment with braided devices.

Epilepsy, to tailor the implantation of deep electrodes using complex 3D multimodal data.

Arrhythmias, to identify the arrhythmic substrate and to plan catheter ablation procedures from cardiac MRI.

Osteoporosis, to improve disease management by turning DXA images into 3D patient-specific models.

iso 13485
Galgo Medical SL has been certified by BSI to ISO 13485:2016 under certificate number MD 656038.